ALNY Q4 2024 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$593M+34.9% YoY

Gross Profit

$490M82.7% margin

Operating Income

-$105M-17.7% margin

Net Income

-$84M-14.1% margin

EPS (Diluted)

$-0.65

QoQ Revenue Growth

+18.4%

Cash Flow

Operating Cash Flow

-$95M

Free Cash Flow

-$104M

Stock-Based Comp.

$92M

Balance Sheet

Total Assets

$4.2B

Total Liabilities

$4.2B

Stockholders' Equity

$67M

Cash & Equivalents

$966M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$593M	$440M	+34.9%
Gross Profit	$490M	$354M	+38.6%
Operating Income	-$105M	-$116M	+9.7%
Net Income	-$84M	-$138M	+39.2%

Revenue Segments

Product

$451M87%

GIVLAARI

$65M13%

Geographic Segments

UNITED STATES

$183M64%

Europe

$69M24%

Non-US Or Europe

$33M12%